» Articles » PMID: 34970430

How to Manage: Acute Severe Colitis

Overview
Specialty Gastroenterology
Date 2021 Dec 31
PMID 34970430
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Acute severe ulcerative colitis (ASUC) is a medical emergency which is associated with significant morbidity and a mortality rate of 1%. ASUC requires prompt recognition and treatment. Optimal management includes admission to a specialist gastrointestinal unit and joint management with colorectal surgeons. Patients need to be screened for concomitant infections and thromboprophylaxis should be administered to mitigate against the elevated risk of thromboembolism. Corticosteroids are still the preferred initial medical therapy but approximately 30%-40% of patients fail steroid therapy and require rescue medical therapy with either infliximab or cyclosporine. Emergency colectomy is required in a timely manner for patients who fail rescue medical therapy to minimise the risk of adverse post-operative outcomes. We discuss current and emerging evidence in the management of ASUC and outline management approaches for clinicians involved in managing ASUC.

Citing Articles

Post-hospitalization Short Versus Long Steroid Taper Strategies in Patients With Acute Severe Ulcerative Colitis: A Comparison of Clinical Outcomes.

Chadalavada P, Afraz S, AlGhadir-AlKhalaileh M, Suarez Z, Swartz A, Rashid M Crohns Colitis 360. 2024; 6(2):otae025.

PMID: 38711857 PMC: 11071514. DOI: 10.1093/crocol/otae025.


Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.

Naganuma M, Nakamura N, Kunisaki R, Matsuoka K, Yamamoto S, Kawamoto A J Gastroenterol. 2024; 59(4):302-314.

PMID: 38277006 DOI: 10.1007/s00535-024-02079-x.

References
1.
Burisch J, Katsanos K, Christodoulou D, Barros L, Magro F, Pedersen N . Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. J Crohns Colitis. 2018; 13(2):198-208. DOI: 10.1093/ecco-jcc/jjy154. View

2.
Surawicz C, Brandt L, Binion D, Ananthakrishnan A, Curry S, Gilligan P . Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4):478-98. DOI: 10.1038/ajg.2013.4. View

3.
Turner D, Walsh C, Steinhart A, Griffiths A . Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2006; 5(1):103-10. DOI: 10.1016/j.cgh.2006.09.033. View

4.
Murthy S, Steinhart A, Tinmouth J, Austin P, Nguyen G . Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients. Gut. 2012; 61(10):1410-6. DOI: 10.1136/gutjnl-2011-301978. View

5.
Ho G, Mowat C, Goddard C, Fennell J, Shah N, Prescott R . Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004; 19(10):1079-87. DOI: 10.1111/j.1365-2036.2004.01945.x. View